Enveric Biosciences Q1 net loss narrows as funding rises

Enveric Biosciences

15/05/2026 13:09

Overview

US biotechnology firm's Q1 net loss narrowed yr/yr, with loss per share at $1.08

Company raised $2.8 mln in gross proceeds during Q1 and added further funding post-quarter

Enveric advanced EB-003 preclinical studies and strengthened its intellectual property portfolio

Outlook

Company expects cash balance to fund operations into the first qtr of fiscal yr 2027

Enveric plans to submit IND for EB-003 and begin first-in-human clinical trials

Company sees supportive policy environment for innovation in mental health therapies

Result Drivers

PIPELINE INVESTMENT - Ongoing preclinical development of lead candidate EB-003 drove spending in Q1

INTELLECTUAL PROPERTY - Co strengthened its IP portfolio with new patent issuances and resolution of a post-grant review petition

CAPITAL RAISES - Gross proceeds of $2.8 mln raised in Q1 and further funds secured post-quarter to support operations

Company press release: ID:nBw4gQHPja

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$1.08
Q1 Net Income
-$1.60 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)